The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

Julia Salih(University of Tübingen), Matthias Krusch(Zero to Three)
International Journal of Cancer
February 8, 2010
Cited by 90


Related Papers

No related papers found

Powered by citation graph analysis